Welcome to our dedicated page for HCW Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCW Biologics Inc. filings document a clinical-stage biopharmaceutical issuer developing fusion immunotherapeutics through the TOBI and TRBC platforms. Its SEC records include 8-K reports for operating results, clinical and regulatory program updates, material agreements, licensing activity and Nasdaq-related corporate events, along with registration statements covering securities offerings and related capital-structure disclosures.
HCWB proxy and governance filings describe annual meeting matters, shareholder voting procedures and bylaw amendments, including quorum provisions. The company’s formal disclosures also address product-candidate development, financial condition, emerging growth company status, risk factors, ownership and governance controls relevant to its public-company reporting profile.
HCW Biologics Inc. entered into a follow-on public offering of 2,477,292 units at $0.6055 per unit, raising approximately $1.5 million in gross proceeds. Each unit includes one share of common stock or a pre-funded warrant plus one common stock warrant.
The common stock warrants carry a $0.6055 exercise price, become exercisable only after stockholder approval under Nasdaq rules, and expire five years after that approval. Pre-funded warrants are exercisable immediately at $0.0001 per share and remain outstanding until fully exercised.
The company also agreed, subject to stockholder approval, to reduce the exercise price of existing warrants to purchase up to 3,020,410 shares from $2.41 to $0.6055 per share. Net proceeds are intended for preclinical and clinical development, including trials for lead candidate HCW9302, and for general corporate purposes.
HCW Biologics Inc. is offering 2,477,292 Units, each consisting of one share of Common Stock (or a Pre-Funded Warrant in certain cases) and one Common Stock Warrant, at $0.6055 per Unit for gross proceeds of approximately $1.5 million on a reasonable best efforts basis.
Each Common Stock Warrant is exercisable for one share at an exercise price of $0.6055 and expires five years after any required Shareholder Approval. Pre-Funded Warrants are exercisable at $0.0001 and offered to avoid beneficial ownership exceeding 4.99% (or up to 9.99% at holder election). The offering is expected to close in a single issuance and delivery is anticipated on or about February 19, 2026. The Company disclosed a Nasdaq quoted share price of $0.6011 as of February 17, 2026.
HCW Biologics Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 400,957 shares, representing 9.99% of the company's common stock. The filing states shared voting and dispositive power over the 400,957 shares.
The Schedule 13G notes the Master Fund, a Cayman Islands exempted company and advisory client of Armistice Capital, has the right to receive dividends or proceeds from sale of the reported securities. The filing is a joint statement by Armistice Capital and Steven Boyd.
HCW Biologics Inc. is filing an S-1 to offer up to 7,691,124 Units, each made up of one share of common stock (or a pre-funded warrant) plus one common stock warrant, on a reasonable best efforts basis for assumed gross proceeds of about $5 million.
The offering has no minimum, no escrow and may close with significantly less capital raised, which the company plans to use mainly for clinical development of HCW9302, broader R&D, business development, IP expansion and general corporate purposes. New investors face immediate dilution, and common stock warrants will only be exercisable if required shareholder approval is obtained.
The prospectus highlights substantial doubt about HCW Biologics’ ability to continue as a going concern, significant past-due payables including construction and legal obligations, and a history of Nasdaq listing compliance issues, though the company recently regained compliance with the equity rule. It also details a restructured license with Trimmune for HCW11-006, providing a $3.5 million upfront package split between cash and equity, and describes early-stage clinical progress for autoimmune indications.
HCW Biologics Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the original S-1 unchanged and primarily refreshes and compiles the exhibit index, including various corporate governance, financing, licensing and commercial agreements.
The filing states that effectiveness will occur after further amendment or SEC action under Section 8(a) of the Securities Act. It is signed on behalf of the company by Founder and Chief Executive Officer Hing C. Wong and other directors and officers, confirming their authorization of the updated registration materials.
HCW Biologics Inc. entered into an exclusive worldwide license agreement with WY Biotech’s newly formed joint venture, Beijing Trimmune Biotech, for certain in vivo applications of its preclinical molecule HCW11-006. Trimmune will develop and commercialize the molecule and fund the first Phase 1 trial in China for solid tumors.
HCW Biologics is receiving a $3.5 million upfront cash license fee, paid in two installments, plus a minority co‑founder equity stake in Trimmune currently valued at about $3.5 million. The company may also receive development milestone payments, double‑digit royalties on future product sales, and a share of proceeds from future transactions involving HCW11-006.
HCW Biologics retains a payment‑free, milestone‑free, and royalty‑free option to recapture rights to HCW11-006 for in vivo applications in the Americas after the Phase 1 trial in China. If exercised, HCW Biologics and Trimmune would co‑develop the drug with each party funding costs in its territory, while coordinating clinical and business development efforts.
HCW Biologics Inc. is seeking to raise up to $10,000,000 through a reasonable best efforts offering of up to 9,523,810 shares of common stock, pre-funded warrants, or a combination, at an assumed price of $1.05 per share.
The company is a clinical-stage immunotherapy developer focused on chronic inflammation and age-related diseases, with lead candidate HCW9302 now in a first-in-human Phase 1 trial for alopecia areata. A 1-for-40 reverse stock split and prior warrant inducement generated additional flexibility and about $4.0 million of gross proceeds.
HCW Biologics reports cash and cash equivalents of $1.1 million as of September 30, 2025 and cumulative net losses of $106.5 million, with substantial doubt about its ability to continue as a going concern. Payables include $19.4 million of obligations, notably legal fees and construction-related amounts tied to a manufacturing facility dispute.
The company has restructured a global license for HCW11-006 with Trimmune, targeting $7.0 million in combined cash and equity consideration if closing occurs. Nasdaq has granted continued listing subject to the company maintaining compliance with equity and other listing rules through February 16, 2026 under a one-year Panel Monitor period.
HCW Biologics Inc. filed a resale registration statement on Form S-1 covering up to 3,400,033 shares of common stock. These shares include 253,083 Conversion Shares issued when noteholders converted approximately $6.6 million of senior secured notes, up to 126,540 shares issuable upon exercise of related Conversion Warrants, and 3,020,410 Warrant Shares issuable upon exercise of New Warrants held by Armistice Capital Master Fund Ltd. We are told the company will not receive proceeds from selling stockholders’ resales.
The filing describes prior warrant inducement transactions that generated approximately $4.0 million in gross proceeds and a Nasdaq listing history in which HCW regained compliance but must now demonstrate compliance with equity and other rules by December 31 2025 and February 16 2026. The prospectus highlights substantial dilution risk from warrant and share resales, material doubt about the company’s ability to continue as a going concern given $1.1 million in cash as of September 30 2025, and about $19.4 million of past-due obligations, including legal fees and construction payables tied to mechanics lien and foreclosure litigation.
HCW also outlines its immunotherapy pipeline, a key license and co-development deal for preclinical molecule HCW11-006 that could yield a $7.0 million upfront package, and initiation of a Phase 1 trial of lead candidate HCW9302 in alopecia areata.
HCW Biologics Inc. entered into an inducement agreement with a single institutional investor on November 19, 2025. The company reduced the exercise price of the investor’s existing November 2024 and May 2025 warrants from $7.45 per share to $2.66 per share, and the investor immediately exercised these warrants to purchase 1,510,205 shares of common stock. This generated approximately $4.0 million in gross proceeds for the company before fees and expenses.
In exchange for the exercise of the existing warrants, HCW Biologics issued new common stock purchase warrants to the investor for up to 3,020,410 shares at an exercise price of $2.41 per share, which are immediately exercisable and expire five and one-half years after their November 20, 2025 issuance. The company agreed to file a registration statement within 30 days to cover the resale of shares issuable upon exercise of the new warrants and engaged Maxim Group LLC as financial advisor, paying a 6.0% cash fee on the gross proceeds from the warrant exercise and up to $15,000 in reimbursable expenses.